Bhargava | 1dfg

Dr. Heidi Noels and Dr. Yvonne Döring receive the W.H. Hauss Award from the DGAF

19-21 April 2018

Dr. Heidi Noels from the Institute for Molecular Cardiovascular Research at RWTH Aachen University together with Dr. Yvonne Döring from the Institute for Prophylaxis and Epidemiology of Circulatory Diseases at LMU Munich together received the DGAF W.H. Hauss Award 2018 from the German Society for Atherosclerosis Research (DGAF) during the 32nd Annual Meeting of the DGAF in Rauischholzhausen, Germany. They were awarded for their publication "Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence From Mouse and Human Studies." (Circulation. 2017; 136: 388-403). In this work it could be shown that vascular CXCR4 has an atheroprotective function by maintaining the arterial integrity and preserving the endothelial barrier function. In addition, CXCR4 stabilizes a contractile smooth muscle cell phenotype. Targeted enhancement of these CXCR4-mediated protective functions could open up novel therapeutic options in the treatment of atherosclerosis.

The award was sponsored by a long-standing active member of the DGAF, Prof. Dr. Winfried März.

Robert Werner Mertens

MD student

University Hospital RWTH Aachen

Department of Internal Medicine

Project: The role of incretin hormone GLP-2 in septic cardiomyopathy

PI: Michael Lehrke

Robert Werner Mertens

MD student

University Hospital RWTH Aachen

Department of Internal Medicine

Project: The role of incretin hormone GLP-2 in septic cardiomyopathy

PI: Michael Lehrke

Members access

Mechanisms of Cardiovascular Complications in Chronic Kidney Disease

PhD MD Students

Shruti Bhargava

PhD student – Marie Curie ITN INCTRICARE

University Hospital RWTH Aachen

Institute for Molecular

Cardiovascular Research

Project: Characterization of the recently identified “Calcification blocking factor” (CBF) and isolation of unknown mediators inhibiting calcification processes.

PI: Joachim Jankowski

This project has the following objectives:

- To identify the active site of CBF

- Development of a peptide mimic for therapeutic application of CBF

-Study the impact of this peptide in the context of isolated systolic hypertension

- Screen chromatographic fractions from Adrenal glands and plasma to identify the unknown Mediators involved in the calcification process

BACK TO OVERVIEW